Literature DB >> 6446259

Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers.

J N Parsons, J M Romano, M E Levison.   

Abstract

The pharmacokinetics of 1-oxa-beta-lactam (LY127935), a new semisynthetic beta-lactam antibiotic, was studied in four healthy adult volunteers (mean age of 27 years, mean body surface area +/- standard error [SE] of 1.87 +/- 0.08 m(2), and mean creatinine clearance +/- SE of 116 +/- 12 ml/min per 1.73 m(2)). Immediately after completion of a 1-g, 20-min intravenous (i.v.) infusion, the mean serum level +/- SE was 70.7 +/- 8.5 mug/ml. After a 1-g intramuscular (i.m.) injection, peak serum levels occurred from 30 min to 1 h, and the mean peak serum level +/- SE was 52.3 +/- 1.6 mug/ml. Beginning at 1 h, the serum concentrations after i.m. administration were higher than those after i.v. administration. At 8 h, the mean serum level +/- SE was 3.8 +/- 0.6 mug/ml after completion of the i.v. infusion and 4.8 +/- 0.7 mug/ml after the i.m. injection. The mean serum half-lives for the beta phase i.v. and i.m. administration were similar (2.3 +/- 0.7 h and 2.4 +/- 0.2 h, respectively). The mean apparent volume of distribution +/- SE was 16.6 +/- 1.9 liters per 1.73 m(2). The mean serum clearance +/- SE of LY127935 was 85.4 +/- 12.7 ml/min per 1.73 m(2), and the mean renal clearance +/- SE was 54.5 +/- 4.4 ml/min per 1.73 m.(2) Urine concentrations of LY127935 were at least 140 mug/ml in each volunteer during the first 12 h after i.m. or i.v. administration. The mean percentages of the dose recovered in the urine +/- SE within 2 h after i.v. or i.m. administration were similar (30 +/- 4 and 34 +/- 11, respectively). Only 67 +/- 3% and 75 +/- 13% were recovered in the urine within 24 h after i.v. and i.m. administration, respectively.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6446259      PMCID: PMC283762          DOI: 10.1128/AAC.17.2.226

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Clinical pharmacology of cefamandole as compared with cephalothin.

Authors:  I W Fong; E D Ralph; E R Engelking; W M Kirby
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

2.  Conversion of penicillin N to cephalosporin(s) by cell-free extracts of Cephalosporium acremonium.

Authors:  M Kohsaka; A L Demain
Journal:  Biochem Biophys Res Commun       Date:  1976-05-17       Impact factor: 3.575

3.  Pharmacokinetics of cefazolin compared with four other cephalosporins.

Authors:  W M Kirby; C Regamey
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

4.  Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds.

Authors:  H C Neu
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

5.  Clinical and in vitro evaluation of cefazolin, a new cephalosporin antibiotic.

Authors:  K Ries; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

  5 in total
  31 in total

1.  Effect of probenecid on the pharmacokinetics of moxalactam.

Authors:  K A DeSante; K S Israel; G L Brier; J D Wolny; B L Hatcher
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

2.  Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.

Authors:  K S Israel; H R Black; G L Brier; J D Wolny; K A DeSante
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

3.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

4.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

5.  Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis.

Authors:  S Srinivasan; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

6.  Moxalactam therapy of serious infections.

Authors:  P Van der Auwera; N Clumeck; Y Van Laethem; R Vanhoof; J P Butzler
Journal:  Infection       Date:  1983 Jul-Aug       Impact factor: 3.553

7.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

8.  Latamoxef and the newborn.

Authors:  J de Louvois; J James; A Mulhall
Journal:  Arch Dis Child       Date:  1984-04       Impact factor: 3.791

9.  Steady-state moxalactam pharmacokinetics in patients: noncompartmental versus two-compartmental analysis.

Authors:  D J Swanson; D P Reitberg; I L Smith; P B Wels; J J Schentag
Journal:  J Pharmacokinet Biopharm       Date:  1983-08

10.  Serum bactericidal activity of moxalactam and cefotaxime with and without tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  H Lagast; S H Zinner; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.